Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 248

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 248
---
 Agreement was cancelled.

| c. | Going concern and management plans |

The accompanying condensed unaudited
financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities
in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development,
clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues.
The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of June 30, 2024, the
Company’s accumulated deficit was $39,740. The Company has funded its operations to date primarily through equity financing, loans
and the issuance of convertible notes. Management expects that the Company will continue to generate losses from the development, clinical
trials, regulatory activities of its product and from the general administration of its business, which will result in negative cash
flow from operating activity.

Additional funding will be required to
complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization
efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.

While the Company has been successful
in raising financing in the past, it is not probable that the Company will be able to successfully obtain additional financing on a timely
basis on terms acceptable to the Company, or will provide the Company with sufficient funds to meet its objective.

Such conditions and other raise substantial
doubts about the Company’s ability to continue as a going concern. Management’s plans include, but are not limited to an
initial public offering (the “IPO”) in the United States.

<div align='center'>F-6</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 1: | GENERAL (Cont.) |

In addition, in the event the Company
is unable to have its convertible notes converted as planned or their repayment date deferred, the Company will not have sufficient cash
flows and liquidity to finance its business operations as currently contemplated. If such sufficient financing or payment deferral is
not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity,
cease operations and/or seek bankruptcy protection. The